Gland Pharma Ltd's Q4FY25 Quarterly Results

Result Summary

• Gland Pharma Ltd reported a 9.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 91.7%.
• Its expenses for the quarter were up by 12.1% QoQ and 95.2% YoY.
• The net profit decreased 6.0% QoQ and increased 144.6% YoY.
• The earnings per share (EPS) of Gland Pharma Ltd stood at 11.7 during Q4FY25.

Financial Statments for Q4FY25

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Gland Pharma Ltd is a pharmaceutical company that specializes in the development, manufacturing, and marketing of complex injectables. Operating within the pharmaceutical industry, Gland Pharma has a significant presence in the global market, offering a range of products including generic injectables, oncology drugs, and biosimilars. The company is known for its strong focus on research and development, enabling it to maintain a competitive edge in producing high-quality and cost-effective products. Recent developments include strategic expansions and collaborations aimed at enhancing its product portfolio and geographic reach.

Revenue

In the fourth quarter of FY25, Gland Pharma Ltd reported a total income of ₹1579.60 crores, reflecting a 9.5% increase compared to the previous quarter (Q3FY25) and a substantial 91.7% rise year-over-year (YoY) compared to Q4FY24. This significant YoY growth indicates a doubling of total income over the year. The quarter-over-quarter (QoQ) growth in total income suggests a consistent upward trend in revenue generation. These figures highlight the company's ability to expand its revenue base effectively over the designated periods.

Profitability

Gland Pharma Ltd's profitability metrics for Q4FY25 show a mixed performance. The profit before tax for this period was ₹298.23 crores, which represents a slight decrease of 0.4% QoQ compared to Q3FY25. However, there was a notable increase of 168.3% YoY from Q4FY24. The profit after tax stood at ₹192.42 crores, marking a 6.0% decline from the previous quarter but a significant increase of 144.6% from the same period last year. The earnings per share (EPS) followed a similar pattern with a 5.6% decrease QoQ to ₹11.70, yet it increased by 143.8% YoY. The tax expense rose by 11.8% QoQ and 225.9% YoY, indicating changes in the company's tax liabilities affecting net profitability.

Operating Metrics

Analyzing the operating metrics of Gland Pharma Ltd, total expenses for Q4FY25 were ₹1281.37 crores, reflecting a 12.1% increase compared to Q3FY25 and a 95.2% rise compared to the same quarter in the previous year. These increases in expenses are in line with the revenue growth, indicating a proportional escalation in operational costs. The trend in expenses suggests that the company is scaling its operations, which is also evident in the revenue figures. The increase in expenses, while significant, appears to be managed in a way that continues to support overall profitability growth on an annual basis.